(19)
(11) EP 3 873 442 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.02.2025 Bulletin 2025/09

(45) Mention of the grant of the patent:
18.12.2024 Bulletin 2024/51

(21) Application number: 19880284.5

(22) Date of filing: 29.10.2019
(51) International Patent Classification (IPC): 
A61K 31/045(2006.01)
A61K 31/22(2006.01)
A61P 3/00(2006.01)
 A61K 31/05(2006.01)
A61K 31/19(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 3/00; A61K 9/14; A61K 9/4808; A61K 31/19; A61K 31/05
 
C-Sets:
  1. A61K 31/19, A61K 2300/00;
  2. A61K 31/05, A61K 2300/00;
(86) International application number:
PCT/US2019/058676
(87) International publication number:
WO 2020/092451 (07.05.2020 Gazette 2020/19)

(54)

A COMPOSITION FOR WEIGHT LOSS OR WEIGHT MANAGEMENT COMPRISING BETA-HYDROXYBUTYRATE AND CANNABIDIOL

ZUSAMMENSETZUNG FÜR DEN GEWICHTSVERLUST ODER DAS GEWICHTSMANAGEMENT, DIE BETA-HYDROXYBUTYRAT UND CANNABIDIOL ENTHÄLT

COMPOSITION POUR LA PERTE DE POIDS OU LA GESTION DU POIDS COMPRENANT DU BÊTA-HYDROXYBUTYRATE ET DU CANNABIDIOL

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 29.10.2018 US 201862752170 P

(43) Date of publication of application:
08.09.2021 Bulletin 2021/36

(73) Proprietor: Axcess Global Sciences, LLC
Salt Lake City, UT 84106 (US)

(72) Inventors:
  • LOWERY, Ryan
    Tampa, FL 33607 (US)
  • WILSON, Jacob
    Tampa, FL 33609 (US)
  • LACORE, Terry
    Melissa, TN 75454 (US)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)


(56) References cited: : 
WO-A1-2005/077348
WO-A1-2012/024611
WO-A2-2008/021394
US-A1- 2014 350 105
US-A1- 2017 296 520
 WO-A1-2007/138322
WO-A1-2017/184788
US-A1- 2009 306 221
US-A1- 2017 296 501
US-B2- 8 071 641
   
  • FABIO ARTURO IANNOTTI ET AL: "Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 176, no. 10, 9 September 2018 (2018-09-09), pages 1568 - 1584, XP071124696, ISSN: 0007-1188, DOI: 10.1111/BPH.14460
  • ALLENDORFER JANE B ET AL: "Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy", EPILEPSY AND BEHAVIOR, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 70, 18 January 2017 (2017-01-18), pages 349 - 354, XP085033476, ISSN: 1525-5050, DOI: 10.1016/J.YEBEH.2016.11.020
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).